NASDAQ:BRTX
BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.'s revenue fell 10.3% in fiscal 2025 to $359,700 while operating margin fell to −4350.1%. Free cash flow was −$10.9M, −3031.7% of revenue, and the diluted share count rose 15.8%.Summary generated from BioRestorative Therapies, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$359,700
Revenue growth−10.3%
Revenue, 5-yr CAGR+36.1%
Gross margin93.4%
Operating margin−4350.1%
Net margin−3959.4%
ROICn/a
Return on equity−320.5%
Debt / equityn/a
Free cash flow−$10.9M
FCF margin−3031.7%
Share count change+15.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | −26 | −19 | −15 | −12 | −16 |
| Net income | −44 | −13 | −10 | −9 | −14 |
| Free cash flow | −3 | −6 | −7 | −8 | −11 |
Recent filings
- 8-KDirector or officer change
Oct 9, 2026 - 8-KDirector or officer change
Sep 11, 2026 - 8-K/AAmended change in auditor
Sep 10, 2026 - 8-KAmendment to articles or bylaws
Sep 2, 2026 - 8-KChange in auditor
Sep 2, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 25, 2026 - 8-KOther events
Aug 14, 2026 - 8-KDirector or officer change
Jul 16, 2026